These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 31276602)

  • 1. Optimising low-dose methotrexate for rheumatoid arthritis-A review.
    Lucas CJ; Dimmitt SB; Martin JH
    Br J Clin Pharmacol; 2019 Oct; 85(10):2228-2234. PubMed ID: 31276602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis.
    Bannwarth B; Péhourcq F; Schaeverbeke T; Dehais J
    Clin Pharmacokinet; 1996 Mar; 30(3):194-210. PubMed ID: 8882301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis.
    Dervieux T; Zablocki R; Kremer J
    Rheumatology (Oxford); 2010 Dec; 49(12):2337-45. PubMed ID: 20713496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment.
    Stamp LK; O'Donnell JL; Chapman PT; Zhang M; Frampton C; James J; Barclay ML
    Arthritis Rheum; 2009 Aug; 60(8):2248-56. PubMed ID: 19644853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration.
    Schiff MH; Jaffe JS; Freundlich B
    Ann Rheum Dis; 2014 Aug; 73(8):1549-51. PubMed ID: 24728329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial.
    Goss SL; Klein CE; Jin Z; Locke CS; Rodila RC; Kupper H; Burmester GR; Awni WM
    Clin Ther; 2018 Feb; 40(2):309-319. PubMed ID: 29402521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy.
    Stamp LK; O'Donnell JL; Chapman PT; Zhang M; James J; Frampton C; Barclay ML
    Arthritis Rheum; 2010 Feb; 62(2):359-68. PubMed ID: 20112376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Methotrexate Triglutamate Level Is an Independent Predictor of Adverse Effects in Asian Indian Rheumatoid Arthritis Patients-A Preliminary Study.
    Sandhu A; Dhir V; Bhatnagar A; Dhawan V; Kaur J; Sood A; Naidu S; Ahmad S; Varma N; Sharma A; Sharma S
    Ther Drug Monit; 2017 Apr; 39(2):157-163. PubMed ID: 28107255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefit and risk of methotrexate treatment in rheumatoid arthritis.
    Rau R; Herborn G
    Clin Exp Rheumatol; 2004; 22(5 Suppl 35):S83-94. PubMed ID: 15552520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measuring methotrexate polyglutamates.
    Goodman S
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S24-6. PubMed ID: 21044429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy: oral or subcutaneous methotrexate for rheumatoid arthritis?
    Alsaeedi S; Keystone EC
    Nat Rev Rheumatol; 2014 Oct; 10(10):578-9. PubMed ID: 25090946
    [No Abstract]   [Full Text] [Related]  

  • 12. The issue of bioavailability of oral low dose methotrexate: should we choose only 10 mg of MTX a week in conjunction with anti-TNF therapy?
    Zeidler H
    Ann Rheum Dis; 2014 Aug; 73(8):e50. PubMed ID: 24764450
    [No Abstract]   [Full Text] [Related]  

  • 13. A short-chain methotrexate polyglutamate as outcome parameter in rheumatoid arthritis patients receiving methotrexate.
    Hobl EL; Jilma B; Erlacher L; Duhm B; Mustak M; Bröll H; Högger P; Rizovski B; Mader RM
    Clin Exp Rheumatol; 2012; 30(2):156-63. PubMed ID: 22152098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis.
    Vakily M; Amer F; Kukulka MJ; Andhivarothai N
    J Clin Pharmacol; 2005 Oct; 45(10):1179-86. PubMed ID: 16172183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety of weekly low dose oral methotrexate in an Oriental population with rheumatoid arthritis.
    Thumboo J; Koh WH; Leong KH; Boey ML; Feng PH
    Ann Acad Med Singap; 1997 Mar; 26(2):205-9. PubMed ID: 9208075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of correlation between pharmacokinetics and efficacy of low dose methotrexate in patients with rheumatoid arthritis.
    Lafforgue P; Monjanel-Mouterde S; Durand A; Catalin J; Acquaviva PC
    J Rheumatol; 1995 May; 22(5):844-9. PubMed ID: 8587070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methotrexate and Rheumatoid Arthritis: Current Evidence Regarding Subcutaneous Versus Oral Routes of Administration.
    Bianchi G; Caporali R; Todoerti M; Mattana P
    Adv Ther; 2016 Mar; 33(3):369-78. PubMed ID: 26846283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal administration and dosage of methotrexate.
    Braun J
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S46-51. PubMed ID: 21044433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe pancytopenia associated with low-dose methotrexate therapy for rheumatoid arthritis.
    Calvo-Romero JM
    Ann Pharmacother; 2001 Dec; 35(12):1575-7. PubMed ID: 11793624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safe prescribing of methotrexate for rheumatoid arthritis.
    Kirkham BW
    Med J Aust; 1995 Sep; 163(5):278. PubMed ID: 7565224
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.